CN103687589A - Cb-183，315组合物和相关方法 - Google Patents

Cb-183，315组合物和相关方法 Download PDF

Info

Publication number
CN103687589A
CN103687589A CN201280025551.2A CN201280025551A CN103687589A CN 103687589 A CN103687589 A CN 103687589A CN 201280025551 A CN201280025551 A CN 201280025551A CN 103687589 A CN103687589 A CN 103687589A
Authority
CN
China
Prior art keywords
sucrose
solid
formulations
formulation
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280025551.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·奥康纳
S·孙
G·奈克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Publication of CN103687589A publication Critical patent/CN103687589A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280025551.2A 2011-05-26 2012-05-24 Cb-183，315组合物和相关方法 Pending CN103687589A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490584P 2011-05-26 2011-05-26
US61/490,584 2011-05-26
PCT/US2012/039476 WO2012162567A1 (en) 2011-05-26 2012-05-24 Cb-183,315 compositions and related methods

Publications (1)

Publication Number Publication Date
CN103687589A true CN103687589A (zh) 2014-03-26

Family

ID=46208839

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280025551.2A Pending CN103687589A (zh) 2011-05-26 2012-05-24 Cb-183，315组合物和相关方法

Country Status (12)

Country Link
US (2) US20130109633A1 (enExample)
EP (1) EP2714012A1 (enExample)
JP (1) JP2014515371A (enExample)
KR (1) KR20140037877A (enExample)
CN (1) CN103687589A (enExample)
AR (1) AR086576A1 (enExample)
BR (1) BR112013030369A2 (enExample)
CA (1) CA2837174A1 (enExample)
MX (1) MX2013013760A (enExample)
RU (1) RU2013157188A (enExample)
TW (1) TW201300124A (enExample)
WO (1) WO2012162567A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476704B (zh) * 2016-04-08 2022-08-16 港大科桥有限公司 抗菌环脂肽
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
WO2010075215A1 (en) * 2008-12-22 2010-07-01 Cubist Pharmaceuticals, Inc. Novel antibacterial agents for the treatment of gram positive infections
CN102060914A (zh) * 2009-11-13 2011-05-18 华东理工大学 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044271A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
AU2002246688A1 (en) * 2000-12-18 2002-07-30 Altus Biologics Inc. Methods for preparing purified daptomycin
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
BR112012012406B1 (pt) * 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
WO2010075215A1 (en) * 2008-12-22 2010-07-01 Cubist Pharmaceuticals, Inc. Novel antibacterial agents for the treatment of gram positive infections
CN102060914A (zh) * 2009-11-13 2011-05-18 华东理工大学 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WWW.CUBIST.COM: "Cubist制药公司关于CXA-101用于复杂性尿路感染治疗的Ⅱ期临床试验结果达到预期目标", 《国外医药（抗生素分册）》, vol. 31, no. 4, 31 December 2010 (2010-12-31), pages 146 *

Also Published As

Publication number Publication date
RU2013157188A (ru) 2015-07-10
TW201300124A (zh) 2013-01-01
MX2013013760A (es) 2014-01-08
BR112013030369A2 (pt) 2016-12-13
KR20140037877A (ko) 2014-03-27
US20140135273A1 (en) 2014-05-15
US20130109633A1 (en) 2013-05-02
CA2837174A1 (en) 2012-11-29
AR086576A1 (es) 2014-01-08
EP2714012A1 (en) 2014-04-09
WO2012162567A1 (en) 2012-11-29
JP2014515371A (ja) 2014-06-30

Similar Documents

Publication Publication Date Title
JP6797980B2 (ja) ルカパリブの高投与力価錠剤
CA2703313C (en) Oral dosage forms comprising licarbazepine acetate
KR101552033B1 (ko) 약학 조성물
KR100669279B1 (ko) 아지트로마이신의 습식 제립 방법
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
KR102759845B1 (ko) 2-｛4-[n-(5,6-디페닐피라진-2-일)-n-이소프로필아미노]부틸옥시｝-n-(메틸술포닐)아세트아미드를 함유하는 의약 조성물
US10071059B2 (en) Co-processed tablet excipient composition its preparation and use
KR101324862B1 (ko) 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법
KR20100015764A (ko) 프레가발린을 포함하는 안정한 약학적 조성물
CN101721410B (zh) 硫酸氢氯吡格雷的固体药物组合物
CN103687589A (zh) Cb-183，315组合物和相关方法
EP1849830A1 (en) Finely divided composition containing poorly water soluble substance
EP3290037A1 (en) Pharmaceutical composition for oral administration
KR20160002177A (ko) 오셀타미비어 유리염기를 포함하는 약학 조성물
EP3875088A1 (en) Package for medical composition containing anti-tumor agent
EP2906203B1 (en) Effervescent cefdinir formulation
WO2012165621A1 (ja) リマプロストとβ－シクロデキストリンを含有する錠剤
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
EP2946771B1 (en) Water-dispersible tablet formulation comprising deferasirox
WO2019163822A1 (ja) 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
KR100783286B1 (ko) 클로피도그렐 우선성 광학이성체의 유리염기를 함유하는고형의 약제학적 조성물
JP2022016561A (ja) 固形製剤及びその製造方法
JP3681185B2 (ja) 錠剤製造用ニフェジピン固体粒子組成物
HK40115604A (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
KR100653388B1 (ko) 안정성이 우수한 ａｃｅ 저해제를 포함하는 약제학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150923

Address after: new jersey

Applicant after: Schering Corporation

Address before: Massachusetts, USA

Applicant before: Hydra Biosciences Inc

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140326